Pleural involvement is one of the most frequent extrapulmonary manifestations of tuberculosis.' Organisation and fibrosis of the pleural exudate can result in long term pleural complications such as thickening, calcification, or fibrosis, causing restrictive ventilatory defects.
The treatment of tuberculous pleurisy includes the use of corticosteroids as adjuvant therapy to provide a prompt relief of the symptoms, to hasten absorption of fluid, and to prevent fibrosis and adhesions. Most information about adjuvant use of corticosteroids is based on uncontrolled studies and in trials using non-bactericidal drugs.23 Nowadays, even though the use of corticosteroids is still being recommended,' there is no convincing evidence of the advantage of their use in the treatment of this disease.
For the treatment of tuberculous pleurisy the same regimen as for pulmonary tuberculosis is usually recommended. However, Dutt et al have demonstrated the efficacy of a six month regimen containing rifampicin and isoniazid for smear negative, culture positive pulmonary tuberculosis,7 and the same authors have recently reported on the efficacy of this two drug regimen for pleural tuberculosis. 8 We present a prospective, randomised, double blind, placebo controlled study evaluating the role of corticosteroids in the control of fever and in the prevention of long term pleural complications of tuberculous pleurisy.
Methods
All patients admitted to the hospital for a pleural effusion of tuberculous aetiology between January 1985 and December 1992 were entered into the study. A definite microbiological or pathological diagnosis was obtained in 63% of all the patients. Patients with HIV infection were excluded. Further clinical and epidemiological data on the patients are shown in the table. Patients received isoniazid, 5 mg/kg/day or a total daily dose of 300 mg, and rifampicin, 10 mg/kg/day or a total daily dose of 600 mg/day, once a day for six months as a combination tablet.
Additionally, patients were randomly assigned to receive, in a double blind fashion, either prednisone (corticosteroid group) or placebo (placebo group). Prednisone was administered in a single oral dose of 1 mg/kg/day during the first 15 days, and then gradually tapered off as follows: to 0 5 mg/kg/day from day 16-20 of treatment, then to 0-25 mg/kg/ day from day 21-26, and finally to 0 10 mg/kg/ day for the remaining days of the month. The total period of corticosteroid (or placebo) treatment was 30 days.
Chest radiography, standard spirometric tests (forced vital capacity (FVC), forced expiratory volume in one second (FEVy), and %FEVI) (Vicatest VCT-4, Mijnhardt BV, Holland), blood biochemistry, and complete blood count were performed on all the patients at the entry into the study before the introduction of treatment. Our procedure for the routine laboratory analysis of pleural fluid in tuberculous pleurisy has been previously reported.9
Before the patient was discharged, pleural fluid was drained until a third ofthe hemithorax was observed to be occupied in a standard chest radiograph. On discharge the patients were regularly seen in the outpatient clinic to monitor the course of the disease, drug compliance, and possible side effects. Chest radiography and standard spirometric tests were repeated at months 1, 2, 4, 6, and 12.
Analytical assessments were performed at months 1, 2, and 6. The effects of corticosteroids were eva by (1) days of fever after introduction treatment; (2) FVC at the end ofthe trea (3) maximal pleural thickening whic measured in millimetres at the costal i of the affected hemithorax in a posteroa chest radiograph before and at month, and 12; and (4) rate of reabsorption whi obtained as follows. A line was drawn fr4 apex of the lung to the half point in the of the liquid profile on the affected sid and to the mid point of the hemidiaphra curve of the contralateral hemithorax (I shown in fig 1 (table) . The duration of fever during treatment was similar in both groups: a mean duration of 3-32 (range 0-50) days for the corticosteroid group and 4 15 (0-60) days for the placebo group (p>0 05). At the end of the treatment period FVC was also similar in both groups (mean FVC 95% (65-130%) for the steroid group and 95% (63-140%) for the placebo group (p>0.05)).
Data on pleural changes are shown in fig  2. The only slight but significant difference between the two groups was the reabsorption index measured at month 1 of treatment: 89% (76-113%) in the placebo group compared with 93% (70-119%) in the other group (p= 00 1). At the end of the treatment period only one patient in the steroid group (40 mm) and five in the placebo group (15 mm in three cases and 10 mm in the other two) showed some pleural thickening; these differences were not significant.
No side effects due to corticosteroids were observed in the 57 patients treated with prednisone. length of the hemithoraces, an inaccurate result could be expected if the distribution of localisation in both groups was unbalanced. The similar distribution of right (34 in the corticosteroid group and 36 in the placebo group) and left (23 in the corticosteroid group and 24 in the placebo group) effusions in both groups avoided a significant bias. The possible confounding effect of localisation was therefore accounted for by using a two way repeated measures analysis of variance that showed no significant interaction between treatment and localisation, and a significant effect of corticosteroids after one month of treatment (F= 6-82; p=001). Although one patient in the corticosteroid group and five in the placebo group showed some pleural thickening at the end of the study, no significant difference was observed between the two groups ( fig 2) . As expected from the clinical and radiological signs seen at six months, no significant changes in FVC were observed at the end of the treatment.
Reducing the volume of pleural fluid to a third of a hemithorax could exolain the absence of pleural sequelae in both groups. Repeated drainage of the pleural effusion was a common procedure to avoid pleural complications until Grewal et al" reported better results with corticosteroids; however, this positive effect was obtained before the routine use of rifampicin and isoniazid, and better therapeutic regimens were introduced. Our only interest in draining large amounts of fluid was to equalise the volume of liquid to be reabsorbed as a result of antituberculous therapy.
It can be argued that a complete drainage of the hemithorax associated with the use of a drug regimen using pyrazinamide would give better results, but if we consider that tuberculous pleurisy is a disease caused by a small number of bacilli, and that pyrazinamide is bactericidal particularly for slow growing and for intracellular organisms, the clinical relevance of its addition to a regimen containing two good bactericidal drugs is yet to be proven.
Rifampicin diminishes the anti-inflammatory effects of prednisone 2 so that the precise dosage of prednisone cannot be stated in the therapeutic regimen we have used. In fact, the slight differences observed between the two groups may be related, at least in part, to this pharmacological interaction. It could also be argued that by using a larger dose (daily or total) of prednisone, a definite favourable effect could be achieved, but our results in the placebo group support the view that further studies using a higher dose of prednisone are not recommended. We can conclude that the advantage of adding corticosteroids to an antituberculous regimen is not clinically relevant, and that its routine use in the treatment of tuberculous pleurisy is not indicated.
